Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Visudyne Manufacturer QLT Must Pay Sales Royalties To AMD Therapy Patent Inventors

This article was originally published in The Pink Sheet Daily

Executive Summary

Court must still decide whether Massachusetts Ear and Eye Infirmary, which won the patent case, is entitled to payments on past sales of the Novartis-marketed eye treatment.

You may also be interested in...

OSI Puts Eye Disease Franchise On The Market

Ongoing Macugen trials look promising, but OSI chooses to put its R&D funds into diabetes and oncology businesses, CEO tells analysts.

Lucentis’ First Patients Mostly Taken From Macugen, Visudyne & Avastin – Genentech

The company recorded $153 mil. in sales for the macular degeneration product in its first full quarter on the market.

Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)

CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts